NEUROFIBROMA, PLEXIFORM
Clinical trials for NEUROFIBROMA, PLEXIFORM explained in plain language.
Never miss a new study
Get alerted when new NEUROFIBROMA, PLEXIFORM trials appear
Sign up with your email to follow new studies for NEUROFIBROMA, PLEXIFORM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug TURALIO takes on tough childhood cancers
Disease control Recruiting nowThis study is testing a drug called TURALIO (pexidartinib) in people aged 3 to 35 whose cancer has come back or not responded to standard treatments. The cancers include certain leukemias, solid tumors, and tumors linked to neurofibromatosis type 1. The goal is to find the safest…
Matched conditions: NEUROFIBROMA, PLEXIFORM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:02 UTC
-
New pill hopes to shrink painful NF1 tumors without surgery
Disease control Recruiting nowThis early-stage study tests a daily pill called PAS-004 in adults with neurofibromatosis type 1 (NF1) who have at least one symptomatic, inoperable nerve tumor (plexiform neurofibroma). The main goals are to find safe doses and understand side effects. The study has two parts: P…
Matched conditions: NEUROFIBROMA, PLEXIFORM
Phase: PHASE1 • Sponsor: Pasithea Therapeutics Corp. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Korean study tracks Koselugo's Real-World impact on rare nerve tumors
Knowledge-focused Recruiting nowThis study is observing 200 people in South Korea who are already prescribed Koselugo for neurofibromatosis type 1 (NF1) with plexiform neurofibromas. Researchers will track side effects and how well the drug works in everyday medical practice. The goal is to confirm the drug's s…
Matched conditions: NEUROFIBROMA, PLEXIFORM
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:50 UTC